**IAW OFFICES** 

RECEIVED CENTRAL FAX CENTER

FEB 2 7 2009

# KILYK & BOWERSOX, P.L.L.C.

Intellectual Property Law

From the Desk of LEONARD D. BOWERSOX 3925 Chain Bridge Road Suite D-401 FAIRFAX, VA 22030

WARRENTON OFFICE 400 Holiday Court, Sulte 102 Warrenton, Virginia 20186

Email: <u>|bowersox@kbpatenflaw.com</u> Website: http://www.kbpatentlaw.com

TEL.: (703) 385-9688 FAC.: (703) 385-9719

(703) 385-9747

PLEASE DIRECT CORRESPONDENCE TO OUR FAIRFAX OFFICE

## FACSIMILE TRANSMISSION COVER SHEET

DATE:

February 27, 2009

UNOFFICIAL BUSINESS

TO:

Examiner Jason M. SIMS

U.S. Patent and Trademark Office

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

EXAMINER:

Jason M. SIMS, Group Art Unit 1631

RE:

U.S. Patent Application No. 10/681,352

DIAGNOSTIC METHOD OF SELECTING APPROPRIATE CANCER TREATMENTS

AND SCREENING METHOD OF MEASURING REAGENTS AND CURATIVE

MEDICINES FOR CANCER PATIENTS

Our Ref.: 3190-044

FROM:

Nahied K. Usman/Leonard D. Bowersox

FAC. NO.:

(571) 273-7540

NUMBER OF PAGES (INCLUDING THIS COVER SHEET): 3

Unofficial Amendments to the Claims Papers Filed Herewith:

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. (571) 273-7540 on February 27, 2009.

Virginia J. Byers

Printed Name:

Signature

THE INFORMATION CONTAINED IN THIS MESSAGE IS CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED. This message may also be an attorney/client communication which is privileged and confidential. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by calling us collect and return the original message to us at the above address by mail. Thank you.

RECEIVED CENTRAL FAX CENTER

FEB 2 7 2009

## <u>UNOFFICIAL COMMUNICATION</u>

U.S. Patent Application No. 10/681,352 Examiner: Jason M. SIMS

Group Art Unit: 1631

Attorney Docket No.: 3190-044

### POSSIBLE AMENDMENTS TO THE CLAIMS

### **Listing of Claims:**

1 - 24 (Canceled)

25. (Previously presented) A method for selecting determining treatments for a cancer patient, comprising:

collecting genomic DNA from the patient;

amplifying the HLA DQB1\* (Major histocompatibility complex, class II, DQ beta

1) gene from the genomic DNA using an automated PCR thermal sequencer;

determining what identifying the amino acids are encoded by at positions 57 and 67 of the amino acid sequence encoded by the HLA DQB1\* (Major histocompatibility complex, class II, DQ beta 1) gene of the patient; and

determining anti-cancer immunotherapy after cancer resection to have a statistically significant probability of prolonging the cancer patient's survival, when by determining that Asp is encoded at position 57 and Val is encoded at position 67 of the amino acid sequence encoded by the HLA DQB1\* (Major histocompatibility complex, class II, DQ beta 1) gene; and

selecting anti-cancer immunotherapy after cancer resection, as a treatment for the patient;

wherein the cancer of the patient comprises is stomach cancer.

26. Canceled.

27. (Withdrawn) A method for determining treatments for a cancer patient, comprising: determining what amino acids are encoded by positions -9, 19, 26, 85, 89, 90, and 116 of the HLA DQB1 \*gene of the patient;

determining what amino acids are encoded by positions 14, 25, 47, and 78, of the DRB1 \*gene of the patient;

determining what amino acids are encoded by positions 9, 36, 55, 69, and 76, of the DPB1 \*gene of the patient; and

correlating the amino acids encoded at the positions with a cancer treatment having the greatest statically significant probability of prolonging the cancer patient's survival, wherein the cancer treatment comprises immunotherapy, chemotherapy, resection, or a combination thereof.

28. (Withdrawn) The method of claim 27, wherein the cancer patient comprises stomach cancer.